- Home
- ARQT
as 07-26-2024 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $26.17 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.76 - $13.17 | Next Earning Date: | 08-06-2024 |
| Revenue: | $106,394,000 | Revenue Growth: | 1545.18% |
| Revenue Growth (this year): | 180.69% | Revenue Growth (next year): | 50.19% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Welgus Howard G. | ARQT | Director | Jul 1 '24 | Sell | $9.31 | 10,000 | $93,141.00 | 180,339 | SEC Form 4 |
| Welgus Howard G. | ARQT | Director | Jun 4 '24 | Sell | $8.01 | 6,458 | $51,755.70 | 170,200 | SEC Form 4 |
| Welgus Howard G. | ARQT | Director | Jun 4 '24 | Sell | $8.00 | 3,542 | $28,336.00 | 176,658 | SEC Form 4 |
| Burnett Patrick | ARQT | See Remarks | May 29 '24 | Sell | $8.75 | 23,000 | $201,319.00 | 209,793 | SEC Form 4 |
| Burnett Patrick | ARQT | See Remarks | May 29 '24 | Sell | $8.72 | 49,952 | $435,386.63 | 209,793 | SEC Form 4 |
| Matsuda Masaru | ARQT | See Remark | May 27 '24 | Sell | $9.01 | 1,775 | $15,988.14 | 188,508 | SEC Form 4 |
| Edwards Larry Todd | ARQT | SVP Chief Commercial Officer | May 16 '24 | Sell | $8.98 | 7,640 | $68,581.99 | 140,360 | SEC Form 4 |
| Watanabe Todd Franklin | ARQT | See Remarks | May 2 '24 | Sell | $8.74 | 13,783 | $120,433.10 | 860,750 | SEC Form 4 |
| Burnett Patrick | ARQT | See Remarks | May 2 '24 | Sell | $8.74 | 9,555 | $83,489.68 | 259,745 | SEC Form 4 |
| Matsuda Masaru | ARQT | See Remark | May 2 '24 | Sell | $8.74 | 5,016 | $43,828.80 | 185,408 | SEC Form 4 |
| Moore Matthew Richard | ARQT | SVP and Chief Business Officer | May 1 '24 | Sell | $8.74 | 4,681 | $40,901.64 | 145,505 | SEC Form 4 |
| Matsuda Masaru | ARQT | See Remark | Mar 4 '24 | Sell | $11.12 | 3,760 | $41,815.71 | 190,424 | SEC Form 4 |
| Burnett Patrick | ARQT | See Remarks | Mar 4 '24 | Sell | $11.12 | 4,782 | $53,181.58 | 269,300 | SEC Form 4 |
| Watanabe Todd Franklin | ARQT | See Remarks | Mar 4 '24 | Sell | $11.12 | 14,903 | $165,739.24 | 874,533 | SEC Form 4 |
| Heron Patrick J | ARQT | Director | Mar 4 '24 | Buy | $9.50 | 21,052 | $199,994.00 | 8,785,284 | SEC Form 4 |
| Moore Matthew Richard | ARQT | SVP and Chief Business Officer | Mar 4 '24 | Sell | $11.12 | 3,468 | $38,568.32 | 146,020 | SEC Form 4 |
| Watanabe Todd Franklin | ARQT | See Remarks | Feb 28 '24 | Sell | $10.60 | 2,465 | $26,129.00 | 889,436 | SEC Form 4 |
| Burnett Patrick | ARQT | See Remarks | Jan 2 '24 | Sell | $3.54 | 1,325 | $4,691.56 | 57,032 | SEC Form 4 |
| Matsuda Masaru | ARQT | See Remark | Nov 18 '23 | Sell | $1.98 | 1,850 | $3,661.15 | 46,634 | SEC Form 4 |
| Watanabe Todd Franklin | ARQT | See Remarks | May 31 '23 | Buy | $6.38 | 1,463 | $9,333.94 | 515,145 | SEC Form 4 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Arcutis Biotherapeutics Submits Supplemental New Drug Application to US FDA for Psoriasis Treatment
GlobeNewswire
4 days ago
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
GlobeNewswire
5 days ago
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
Zacks
7 days ago
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Zacks
9 days ago
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
Zacks
10 days ago
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
Zacks
11 days ago
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
Zacks
14 days ago
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.